ag 112 has been researched along with dizocilpine in 1 studies
Studies (ag 112) | Trials (ag 112) | Recent Studies (post-2010) (ag 112) | Studies (dizocilpine) | Trials (dizocilpine) | Recent Studies (post-2010) (dizocilpine) |
---|---|---|---|---|---|
19 | 0 | 10 | 77 | 0 | 30 |
Protein | Taxonomy | ag 112 (IC50) | dizocilpine (IC50) |
---|---|---|---|
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.002 | |
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.0149 | |
Lysosomal Pro-X carboxypeptidase | Homo sapiens (human) | 0.0053 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.0149 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.0149 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.0149 | |
Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 0.009 | |
Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 0.029 | |
Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 0.009 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.0149 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.0149 | |
Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | 1.7 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.0149 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 other study(ies) available for ag 112 and dizocilpine
Article | Year |
---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |